| __timestamp | Neurocrine Biosciences, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 72471000 |
| Thursday, January 1, 2015 | 32480000 | 89204000 |
| Friday, January 1, 2016 | 68081000 | 106010000 |
| Sunday, January 1, 2017 | 169906000 | 137905000 |
| Monday, January 1, 2018 | 248932000 | 159888000 |
| Tuesday, January 1, 2019 | 354100000 | 158425000 |
| Wednesday, January 1, 2020 | 433300000 | 200677000 |
| Friday, January 1, 2021 | 583300000 | 304759000 |
| Saturday, January 1, 2022 | 752700000 | 377221000 |
| Sunday, January 1, 2023 | 887600000 | 336361000 |
| Monday, January 1, 2024 | 1007200000 |
Unveiling the hidden dimensions of data
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Neurocrine Biosciences, Inc. and Supernus Pharmaceuticals, Inc. have been navigating this financial landscape since 2014. Over the past decade, Neurocrine Biosciences has seen a staggering increase in SG&A expenses, growing nearly 50 times from 2014 to 2023. In contrast, Supernus Pharmaceuticals has managed a more modest increase, with expenses rising by approximately 4.6 times over the same period.
By 2023, Neurocrine's SG&A expenses reached nearly 2.6 times that of Supernus, highlighting a significant divergence in cost management strategies. This trend suggests that while Neurocrine is investing heavily in its operations, Supernus is maintaining a more conservative approach. Investors and industry analysts will find these insights invaluable as they assess the financial health and strategic direction of these two industry players.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? AbbVie Inc. or Supernus Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Insmed Incorporated or Supernus Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Supernus Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.